Table 2.
Characteristics of Study Participants by Autoantibody Status
| Variables | Pol I/III (N=6) |
Topo (N=5) |
CENP (N=8) |
Negative (N=4) |
P-value |
|---|---|---|---|---|---|
| Age at Scleroderma Diagnosis (years), median | 51.8 | 45.1 | 48.9 | 54.6 | 0.511 |
| Age at Cancer Diagnosis (years), median | 51.0 | 64.9 | 60.9 | 56.9 | 0.337 |
| Female sex, no. (%) | 6 (100) | 5 (100) | 7 (87.5) | 4 (100) | 1 |
| Race, no. (%) | 0.391 | ||||
| White | 6 (100) | 4 (80) | 8 (100) | 4 (100) | |
| African-American | 0 (0) | 1 (20) | 0 (0) | 0 (0) | |
| ACR Criteria Met, no. (%)* | 6 (100) | 5 (100) | 5 (62.5) | 3 (75) | 0.176 |
| Scleroderma Classification, no. (%) | <0.001 | ||||
| Limited | 0 (0) | 3 (60) | 8 (100) | 3 (75) | |
| Diffuse | 6 (100) | 2 (40) | 0 (0) | 1 (25) | |
| Scleroderma Duration at Cancer Diagnosis (years), median |
−1.2 | 13.4 | 11.1 | 2.3 | 0.027 |
| Raynaud’s Duration at Cancer Diagnosis (years), median |
0.25 | 13.2 | 23.8 | 4.0 | 0.113 |
| Smoking, no. (%) | 0.832 | ||||
| Never | 4 (66.7) | 2 (40) | 5 (62.5) | 3 (75) | |
| Former | 2 (33.3) | 3 (60) | 3 (37.5) | 1 (25) | |
| Disease Severity, no. (%) | |||||
| Severe Raynaud’s Phenomenon ** | 1 (16.7) | 3 (60) | 5 (62.5) | 0 (0) | 0.100 |
| Abnormal General Severity Score § | 4 (66.7) | 2 (40) | 3 (37.5) | 1 (25) | 0.681 |
| History of renal crisis | 2 (33.3) | 0 (0) | 0 (0) | 0 (0) | 0.123 |
| History of myopathy | 2 (33.3) | 0 (0) | 0 (0) | 1 (25) | 0.206 |
| Modified Rodnan Skin Score, median | 36 | 9 | 4 | 6 | 0.012 |
| Interstitial lung disease,╪ no. (%) | 2 (33.3) | 2 (40) | 0 (0) | 1 (25) | 0.231 |
| Pulmonary arterial hypertension,¥ no. (%) | 1 (16.7) | 1 (20) | 2 (25) | 1 (25) | 1 |
| Medications Prior to Cancer Diagnosis, no. (%) | |||||
| Hormone replacement therapy | 1 (16.7) | 1 (20) | 2 (25) | 0 (0) | 0.892 |
| Prednisone | 1 (16.7) | 1 (20) | 1 (12.5) | 0 (0) | 1 |
| Methotrexate | 1 (16.7) | 0 (0) | 1 (12.5) | 0 (0) | 1 |
| Azathioprine | 0 (0) | 1 (20) | 0 (0) | 0 (0) | 0.391 |
| Cyclophosphamide | 0 (0) | 2 (40) | 0 (0) | 0 (0) | 0.063 |
| Mycophenolate mofetil | 0 (0) | 1 (20) | 0 (0) | 1 (25) | 0.202 |
Pol I/III: anti-RNA polymerase I/III, topo: anti-topoisomerase I, CENP: anti-centromere, negative: no autoantibody
*
Remaining patients met CREST criteria.
**
Defined as Medsger Raynaud’s Severity Score ≥2.
§
Defined as Medsger General Severity Score ≥1; based on presence of anemia or weight loss.
╪
Defined by FVC < 70% predicted
¥
Defined by RVSP ≥ 45mmHg or right heart catheterization evidence of PAH.